Researchers Study Improvement in Patient Compliance and Screening Efficacy by Using the EyeArt AI Eye Screening System for Detecting Diabetic Retinopathy

Fusion Marketplace Changes Healthcare Traveler Experience

Fusion Marketplace is a traveler-first driven platform giving healthcare professionals the power to make decisions in their careers that they haven't been able to in the past.

Veranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services Company

As the first phase in building this global entity, Veranex has acquired three complementary solution providers: Ximedica, Quartesian, and Boston Healthcare Associates. By bringing these companies together, Veranex combines the industry’s key pillars of design and engineering, regulatory, clinical, and market access into a single-source solution.

Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that data from scientific studies related to the screening efficacy of the EyeArt® AI Eye Screening System and the impact of using the EyeArt AI System in improving compliance with follow-up ophthalmic care for diabetic retinopathy (DR) will be presented during the American Diabetes Association (ADA) 79th Scientific Sessions from June 7 to 11 in San Francisco.

The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of DR, tested in the real world on more than a half-million patient visits globally with over 2 million images collected in real-world clinical environments. In a prospective, multicenter, pivotal clinical trial, the EyeArt System demonstrated exceptional performance with 95.5% sensitivity, 86.5% specificity and 97.4% imageability against the rigorous ETDRS clinical reference standard while meeting all primary endpoints with p<0.0001.1

Currently, physicians treating patients with diabetes must refer them annually to an eye specialist for DR screening. While DR screening is recommended for all diabetic patients, less than half get screened annually. In contrast, the EyeArt AI Eye Screening System is designed to make in-clinic, real-time DR screening possible for any physician, enabling quick and accurate on-site identification of patients with DR during a diabetic patient’s regular exam, removing the biggest obstacles to annual DR screening and diagnosis: screening access and patient compliance. AI Eye Screening technology allows diabetes care providers to identify patients with referable DR in clinic, in real time, without needing eye care expertise on site, and immediately refer at-risk patients to ophthalmologists for further evaluation and treatment.

The ADA scientific program will feature multiple scientific presentations related to the EyeArt AI Eye Screening System:

  • A late-breaking abstract presented by Bruce Bode, M.D., past president of the American Diabetes Association Georgia Affiliate: Diabetic Retinopathy (DR) Screening Performance of an Artificial Intelligence (AI) System: Analysis from a Pivotal Multicenter Prospective Clinical Trial. The abstract will be presented from 12–1 p.m. on Sunday, June 9. Dr. Bode is a diabetes specialist with Atlanta Diabetes Associates in Atlanta and is currently on the faculty of Emory University as a clinical associate professor in the Department of Medicine.
  • In addition, Eli Ipp, M.D., will present Diabetic Retinopathy (DR) Screening Performance of General Ophthalmologists, Retina Specialists, and Artificial Intelligence (AI): Analysis from a Pivotal Multicenter Prospective Clinical Trial. The abstract will be presented from 12–1 p.m. on Monday, June 10. Dr. Ipp is professor of medicine at the UCLA School of Medicine, and head of the Section of Diabetes and Metabolism at Harbor-UCLA Medical Center.
  • Washington University School of Medicine in St. Louis and the Department of Ophthalmology will present Automated Diabetic Retinopathy Screening in the Primary Care Setting Improves Compliance with Follow-Up Ophthalmic Care. The abstract will be presented on Monday, June 10, from 12–1 p.m.
  • Finally, Eyenuk will present Explaining an Artificial Intelligence (AI) System for Diabetic Retinopathy (DR) Screening in Primary Care on Monday, June 10, from 12–1 p.m.

“By giving clinicians who treat diabetes the right tools, we can help them identify DR sooner and get patients treated faster,” said Kaushal Solanki, Ph.D., founder and CEO of Eyenuk. “The EyeArt AI Eye Screening System is the solution they need to ensure patient compliance, screen regularly and save vision. We’re pleased to be a part of this meeting and share our successful implementation in a number of countries spanning five continents across the globe.”

Eyenuk will showcase its EyeArt AI Eye Screening System at Booth #2007 in the ADA Exhibit Hall at the Moscone Center in San Francisco. The company’s management team will be available to meet with clinical and business partners.



Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles